
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of all heart failure diagnoses.1 Limited medical therapy exists for reducing HFpEF mortality compared to HFrEF. Researchers at the Cleveland Clinic investigated the use of a left atrial assist device (LAAD) in vivo and in an animal model for the management of HFpEF.2
In Vitro Model.
The LAAD is implanted in the mitral valve position and pumps blood from the left atrium (LA) into the left ventricle (LV). It can pump up to 10L/minute to support cardiac output (CO).2